<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97569">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062957</url>
  </required_header>
  <id_info>
    <org_study_id>NF81300148</org_study_id>
    <nct_id>NCT02062957</nct_id>
  </id_info>
  <brief_title>Endovascular Function in Atrial Fibrillation (AF) Patients</brief_title>
  <acronym>HEAF</acronym>
  <official_title>Endovascular Function in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <authority>China: Beijing Municipal Science and Technology Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. recruit 50 patients with atrial fibrillation and 30 controls

        2. endovascular function assessment with Peripheral Arterial Tonometry (PAT)

        3. follow up the occurence of AF
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>endovascular function results</measure>
    <time_frame>Up to 24 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The method to assess the endovascular function is PAT. The index is Reactive hyperemia index (RHI). RHI between patients and control will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>predictive effect of endovascular function on recurrence of AF</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will do the multi-logistic analysis of the recurrence of AF.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>PAT Result</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with AF
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥2 paroxysmal (electrocardiographic documentation of at least 1) AF episodes lasting
             ≥1 hour in duration: (that terminate spontaneously within 7 days or cardioversion is
             performed within 48h of AF onset): or

          -  electrocardiographic documentation of 1 persistent AF episode: (sustained for ≥7 days
             or cardioversion is performed more than 48h after AF onset): or

          -  electrocardiographic documentation of 1 longstanding persistent AF episode:
             (continuous AF of duration &gt;1 year).

        Exclusion Criteria:

          -  patients with cerebralvascular disease

          -  patients with coronary disease

          -  patients with peripheric artery disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Han, Bachelor</last_name>
      <phone>86-10185231512</phone>
    </contact>
    <investigator>
      <last_name>Guangzhen Zhong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 23, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Guangzhen Zhong</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
